RONAN O'CAOIMH, CHIEF EXECUTIVE OFFICER, co-founded Trinity Biotech in 1992 and acted as CFO until 1994 when he became CEO. Prior to joining Trinity, Mr. O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr. O'Caoimh holds a Bachelor of Commerce degree from University College, Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

RORY NEALON, CHIEF OPERATING OFFICER, joined Trinity Biotech in early 2003 from Conduit plc, a telecom services company where he was CFO. Previously Mr.Nealon was employed by Allied Irish Banks plc where he invested equity and short-term mezzaine finance into emerging growth companies. Mr. Nealon holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, the Institute of Taxation in Ireland and the U.K. Institute of Corporate Treasurers.

JIM WALSH, PHD, NON-EXECUTIVE DIRECTOR, joined Trinity Biotech in October 1995. Prior to joining the Company, Dr. Walsh was Managing Director of Cambridge Diagnostics Ireland Limited (CDIL). He was employed with CDIL since 1987. Before joining CDIL he worked with fleming GmbH as Research & Development Manager. Dr. Walsh has a degree in Chemistry and a PhD in Microbiology from University College Galway.

DENIS R. BURGER, PHD, NON-EXECUTIVE DIRECTOR, co-founded Trinity Biotech in June 1992 and acted as Chairman from June 1992 to May 1995. He is currently a non-executive director of the Company. Dr Burger is Chairman, Chief Executive Officer and a director of AVI Biopharma Inc, an Oregon based biotechnology company. Dr Burger is also a 50% partner in Sovereign Ventures, a healthcare consulting and unding firm based in Portland, Oregon. He was a co-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health Sciences University in Portland. Dr Burger received his degree in Bacteriology and Immunology from the University of California in Berkeley in 1965 and his Master of Science and PhD in 1969 in Microbiology and Immunology from the University of Arizona.

PETER COYNE, NON-EXECUTIVE DIRECTOR, joined the board of Trinity Biotech in November 2001 as a non-executive director. Mr Coyne is a director of AIB Corporate Finance, a subsidiary of AIB Group plc, the Irish banking group. He has extensive experience in advising public and private groups on all aspects of corporate strategy. Prior to joining AIB, Mr Coyne trained as a chartered accountant and was a senior manager in Arthur Andersen's Corporate Financial Services practice. Mr Coyne holds a Bachelor of Engineering degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

CLINT SEVERSON, NON-EXECUTIVE DIRECTOR, joined the board of Trinity Biotech in November 2008. Mr. Severson is currently Chairman, President and CEO of Abaxis Inc., a NASDAQ traded diagnostics company based in Union City, California. Since November 2006, Mr. Severson has also served on the Board of Directors of CytoCore, Inc. To date he has accumulated over 30 years experience in the medical diagnostics industry and in 2007 he received the prestigious Entrepreneur of the Year award from Forbes Magazine.

JAMES D. MERSELIS, NON-EXECUTIVE DIRECTOR, joined the board of Directors in Trinity Biotech in February 2009. Mr. Merselis is currently President and CEO of Alverix, Inc., a privately held optoelectronics company developing portable medical diagnostic instruments in cooperation with leading point-of-care (POC) diagnostics companies. Most recently, Mr. Merselis served as President and CEO of HemoSense, Inc. (AMEX: HEM), a point-of-care diagnostics company focused initially on providing patients and physicians with rapid test results to help manage the risk of stroke with the drug warfarin or Coumadin. HemoSense was acquired by Inverness Medical Innovations, Inc. (AMEX: IMA) in late 2007 for $265 million. Prior to his tenure at HemoSense, Mr. Merselis served as President and CEO of Micronics, Inc., a microfluidics company that develops near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. In addition, he held a number of positions over twenty-two years with Boehringer Mannheim Diagnostics (now Roche Diagnostics).